Do-Youn Oh, MD, PhD
Seoul National University Hospital
7
6
4
N/A
0
1
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+3 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (7)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Yung-Jue Bang, MD, PhD
Seoul National University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Tim F Greten, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Ciro Gallo, M.D., Ph.D.
University of Campania Luigi Vanvitelli
Shared therapeutic areas:
Zhaoping Li, MD, PhD
University of California, Los Angeles
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Toshimitsu Tokimoto
Astrazeneca KK
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (7)
Showing 7 of 7 trials
Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
Paclitaxel and Irinotecan in Advanced Gastric Cancer
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer
MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
All 7 trials loaded